Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 438-439

  Alsina, M ^a,b   Landolfi, S ^a,b   Aura, C ^b   Caci, K ^a   Jimenez, J ^b   Prudkin, L ^b   Castro, S ^a   Moreno, D ^b   Navalpotro, B ^a   Tabernero, J ^a,b   Scaltriti, M ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

AGED; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL TIME; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

AGED; BIOMARKERS, TUMOR; CYCLIN E; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84925325841     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu535     Document Type: Letter

References (5)

1. Bass AJ, Thorsson V, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
2. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
3. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575.
4. Bani-Hani KE, Almasri NM, Khader YS et al. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 2005; 11: 1447-1453.
5. Scaltriti M, Eichhorn PJ, Cortes J et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011; 108: 3761-3766.